Off-label use of bedaquiline in children and adolescents with drug-resistant tuberculosis

File Description SizeFormat 
2017 Bdq in children v10.docxAccepted version44.41 kBMicrosoft WordView/Open
17-0303.pdfPublished version346.3 kBAdobe PDFView/Open
Title: Off-label use of bedaquiline in children and adolescents with drug-resistant tuberculosis
Authors: Achar, J
Hewison, C
Cavalheiro, A
Skrahina, A
Cajazeiro, J
Nargiza, P
Herboczek, K
Rajabzoda, A
Hughes, J
Ferlazzo, G
Seddon, JA
Du Cros, P
Item Type: Journal Article
Abstract: Limited information on the use of bedaquiline in children and adolescents has resulted in restriction of its use to adults. This report describes 27 children and adolescents aged <18 years who received bedaquiline during treatment for drug-resistant TB. We report good treatment responses and no cessation due to adverse effects.
Issue Date: 1-Oct-2017
Date of Acceptance: 13-Jun-2017
ISSN: 1080-6059
Publisher: Centers for Disease Control and Prevention
Start Page: 1711
End Page: 1713
Journal / Book Title: Emerging Infectious Diseases
Volume: 23
Issue: 10
Copyright Statement: All materials published in Emerging Infectious Diseases are in the public domain and can be used without permission. Achar J, Hewison C, Cavalheiro AP, et al. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis. Emerging Infectious Diseases. 2017;23(10):1711-1713. doi:10.3201/eid2310.170303.
Keywords: 1108 Medical Microbiology
1117 Public Health And Health Services
1103 Clinical Sciences
Publication Status: Published
Appears in Collections:Department of Medicine
Faculty of Medicine

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx